Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Endourol ; 38(6): 598-604, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38829325

ABSTRACT

Introduction: There are minimal data to guide antibiotic management of patients undergoing holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia. Specifically, management of high-risk patients who are catheter dependent or have positive preoperative urine cultures varies widely. We aimed to evaluate the effect of preoperative antibiotic duration on infectious complications in high-risk patients undergoing HoLEP. Methods: A multi-institutional retrospective review of patients undergoing HoLEP between 2018 and 2023 at five institutions was performed. Patients were defined as high risk if they were catheter-dependent (indwelling urethral catheter, self-catheterization, or suprapubic tube) or had a positive preoperative urine culture. These patients were categorized into long course (>3 days) or short course (≤3 days) of preoperative antibiotics. The primary outcome was 30-day infectious complications defined as a positive urine culture with symptoms. A t-test or Wilcoxon rank-sum test was used for continuous variables and Fisher's exact test was used for categorical variables. Logistic regression analysis was conducted to identify associations with infectious complications. Results: Our cohort included 407 patients, of which 146 (36%) and 261 (64%) were categorized as short course and long course of preoperative antibiotics, respectively. Median preoperative antibiotic duration was 1 day (interquartile range [IQR]: 0, 3 days) and 7 days (IQR: 5, 7 days) in the short and long cohorts, respectively. Thirty-day postoperative infectious complications occurred in 11 (7.6%) patients who received a short course of antibiotics and 5 (1.9%) patients who received a long course of antibiotics (odds ratio 0.24, 95% confidence interval 0.07-0.67; p = 0.009). Variables such as age, positive urine culture, and postoperative antibiotic duration were not significantly associated with postoperative infection after propensity score weighting. Conclusion: In high-risk patients undergoing HoLEP, infectious complications were significantly lower with a long course vs short course of antibiotics. Further prospective trials are needed to identify optimal preoperative antibiotic regimens.


Subject(s)
Anti-Bacterial Agents , Antibiotic Prophylaxis , Lasers, Solid-State , Preoperative Care , Prostatic Hyperplasia , Humans , Male , Aged , Retrospective Studies , Lasers, Solid-State/therapeutic use , Anti-Bacterial Agents/therapeutic use , Prostatic Hyperplasia/surgery , Antibiotic Prophylaxis/methods , Middle Aged , Urinary Tract Infections , Risk Factors , Postoperative Complications/etiology , Aged, 80 and over , Prostatectomy/methods , Prostatectomy/adverse effects , Prostate/surgery
2.
Cancers (Basel) ; 16(10)2024 May 11.
Article in English | MEDLINE | ID: mdl-38791924

ABSTRACT

The landscape of treatment for non-muscle invasive bladder cancer is rapidly changing. A complete and careful transurethral resection is the mainstay of initial treatment and is followed by intravesical therapy in intermediate or high-risk cases. The standard of care is intravesical BCG. Many alternative or additive approaches to this are being explored. We divided this review into three relevant spaces to consider these novel treatment approaches: (1) low-risk disease, for which intravesical therapy is not usually considered, (2) BCG-naïve disease (i.e., considering alternatives to the standard therapy), and (3) BCG-unresponsive disease. We performed a review of published literature and summarized ongoing trials in the United States. Novel approaches that we explored include surgical techniques for resection, alterations in dwell time for intravesical therapy, delivery method and schedule of intravesical therapies, new intravesical therapy agents, and systemic therapies (especially immunotherapy). These are thoroughly outlined throughout this review article, and the numerous modalities being studied demonstrate significant promise for the future treatment of the expanding space of NMIBC.

3.
Can Urol Assoc J ; 16(11): E563-E568, 2022 Nov.
Article in English | MEDLINE | ID: mdl-35704928

ABSTRACT

Urinary tract leiomyomas are rare, benign mesenchymal tumors that are traditionally treated with complete surgical excision. We present three cases of urinary tract leiomyoma - two located in the bladder and one in the ureter. Both bladder leiomyomas were treated with transurethral resection of bladder tumor (TURBT) with no evidence of recurrent disease, while the upper tract leiomyoma was managed with surveillance by patient preference, which to our knowledge, has not been previously described. The ureteral leiomyoma has remained stable at five years followup from initial diagnosis. Given the benign nature of leiomyomas and the overall low recurrence rate reported in the literature, bladder-sparing options should be emphasized when feasible, with active surveillance potentially applicable for highly select patients.

4.
Urol Case Rep ; 39: 101864, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34631429

ABSTRACT

A 57-year-old male presented to the emergency department due to sudden growth of a penile mass. On physical exam, the mass was located on the ventral surface of the penis at the level of the corona and measured 7cm × 4cm x 3.5cm. Ultrasound suggested that it was cystic in nature. The mass was surgically removed, and final pathology revealed a median raphe cyst.

SELECTION OF CITATIONS
SEARCH DETAIL
...